Learn Before
Methods for tracking outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Population selection to track outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion
Brescia COVID-19 Respiratory Severity Scale (BCRSS)
-
"9-category ordinal severity scale ranging from 0 (asymptomatic patient) to 8 (a critically ill patient with tracheal intubation, mechanical ventilation and advanced ICU management"
-
"The BCRSS has been developed through multiple interactions by a multidisciplinary team of intensive care physicians, infectious disease specialists, pneumologists, internists, rheumatologists and immunologists to rapidly assess the patients' respiratory condition. BCRSS classifies the patients' severity based on the need for oxygen supplementation and ventilatory support, offering a step-up therapeutic approach for the use of antiviral and anti-inflammatory drugs. The scale was rapidly adopted at a regional level and used to define pragmatically the patient's response to treatment "
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Brescia COVID-19 Respiratory Severity Scale (BCRSS)
Tocilizumab (TCZ) infusion dosage for study of outcomes among 100 severe COVID-19 patients in Brescia, Italy
Other concurrent therapies in evaluating outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
Population selection to track outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
Brescia COVID-19 Respiratory Severity Scale (BCRSS)
Brescia COVID-19 Respiratory Severity Scale (BCRSS)